Since ER-α36 activates membrane-initiated non-genomic signaling pathways (MAPK [22, 30], AKT [6], and PKC [31]), cell membrane ER-α36 is thought to play a dominant role in driving breast cancer growth and development. Here, PRRT2 is linked to breast cancer.